{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:51:50Z","timestamp":1791474710224,"version":"4.3.4"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"\n Importance<\/jats:title>\n Aggressive variants of papillary thyroid carcinoma (PTC) represent a small but clinically consequential subset and may become radioactive iodine refractory, limiting treatment options. Programmed cell death 1 ligand 1 (PD-L1) has been evaluated in tumor tissue as a potential biomarker in PTC, but evidence for serum PD-L1, particularly in aggressive PTC, is limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether serum PD-L1 levels and tumor PD-L1 expression are associated with aggressive clinicopathologic features of PTC.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study included patients with PTC undergoing serum PD-L1 measurement by enzyme-linked immunosorbent assay and tumor PD-L1 by immunohistochemistry (E1L3N) at the Louisiana State University Health Shreveport and Overton Brooks Veterans Affairs Medical Center. Healthy controls, patients with benign thyroid disease, and patients with PTC (including aggressive and nonaggressive disease) were included. Statistical comparisons were performed using linear and logistic regression. Data were collected from January 2009 to December 2024, and data were analyzed from February to August 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n PTC was classified as aggressive if it demonstrated 1 or more of the following, defined a priori per the 2025 American Thyroid Association Risk of Recurrence framework: (1) macroscopic extrathyroidal extension, (2) bulky or invasive lymphadenopathy, (3) aggressive histology (tall cell, columnar cell, solid, or diffuse sclerosing variant), or (4) distant metastases.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Differences in serum PD-L1 levels and tumor PD-L1 expression between aggressive and nonaggressive PTC; associations between serum PD-L1 and specific aggressive features; and correlation between serum PD-L1 levels and tumor PD-L1 expression. Disease-free survival (DFS) was analyzed using Kaplan-Meier estimator and Cox proportional hazards regression to evaluate the prognostic value of tumor and serum PD-L1 on recurrence outcomes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 156 included patients, 116 (74.4%) were female and 40 (25.6%) were male, with a mean (SD) age of 49.2 (15.6) years. A total of 45 patients were healthy controls, 49 had benign thyroid disease, and 62 had PTC, including 31 with aggressive disease and 31 with nonaggressive disease. Serum PD-L1 levels were markedly higher in patients with aggressive PTC compared with healthy controls (\u03b2\u2009=\u200923.40; 95% CI, 9.12-37.67), benign thyroid disease (\u03b2\u2009=\u200920.78; 95% CI, 6.80-34.77), and nonaggressive PTC (\u03b2\u2009=\u200924.92; 95% CI, 8.95-40.88). On adjusted linear analysis of aggressive features, macroscopic extrathyroidal extension (\u03b2\u2009=\u200942.07; 95% CI, 23.04-61.10) and aggressive histology (\u03b2\u2009=\u2009181.15; 95% CI, 126.08-236.23) were associated with higher serum PD-L1 levels but not bulky\/invasive lymphadenopathy and distant metastasis. Tumor PD-L1 positivity was associated with\n BRAF<\/jats:italic>\n V600E variation in PTC (odds ratio, 5.06; 95% CI, 1.03-30.67), with a stronger association after adjustment for PTC aggressiveness (odds ratio, 6.06; 95% CI, 1.12-43.63). Serum PD-L1 levels were not correlated with tumor PD-L1 expression (\n r<\/jats:italic>\n \u2009=\u20090.17; 95% CI, \u22120.14 to 0.46).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, higher serum PD-L1 levels were associated with aggressive clinicopathologic features of PTC but not tumor PD-L1 expression. Serum PD-L1 may be a useful prognostic biomarker for aggressive PTC, including in settings where tumor PD-L1 assessment may be limited by sampling error and intratumoral heterogeneity.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoto.2026.2200","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:30:22Z","timestamp":1786635022000},"page":"935","source":"Crossref","is-referenced-by-count":0,"title":["Serum and Tumor PD-L1 Expression and Aggressive Clinicopathologic Features in Papillary Thyroid Carcinoma"],"prefix":"10.1001","volume":"152","author":[{"given":"Srivatsa Surya","family":"Vasudevan","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janmaris","family":"Marin Fermin","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Boven","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Gundale","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport"},{"name":"Department of Otolaryngology-Head and Neck Surgery, University of Florida College of Medicine, Jacksonville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Moore-Medlin","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok R.","family":"Khandelwal","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Pathology, LSU-Health Sciences Center, Shreveport, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherie-Ann O.","family":"Nathan","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Louisiana State University Health Sciences Center, Shreveport"},{"name":"Feist-Weiller Cancer Center, LSU-Health Sciences Center, Shreveport, Louisiana"},{"name":"Overton Brooks VA Medical Center, Shreveport, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"ooi260045r1","doi-asserted-by":"publisher","first-page":"e4823","DOI":"10.1210\/clinem\/dgaa690","article-title":"Influence of nomenclature changes on trends in papillary thyroid cancer incidence in the United States, 2000 to 2017.","volume":"105","author":"Kitahara","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ooi260045r2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/618985","article-title":"Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.","volume":"2012","author":"Busaidy","year":"2012","journal-title":"J Thyroid Res"},{"issue":"10","key":"ooi260045r3","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/annonc\/mdp050","article-title":"Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution.","volume":"20","author":"Sciuto","year":"2009","journal-title":"Ann Oncol"},{"issue":"8","key":"ooi260045r4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer.","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"issue":"1","key":"ooi260045r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2021.103204","article-title":"Radiofrequency ablation and thyroid cancer: review of the current literature.","volume":"43","author":"Muhammad","year":"2022","journal-title":"Am J Otolaryngol"},{"issue":"2","key":"ooi260045r6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.mcna.2012.01.002","article-title":"Approach to and treatment of differentiated thyroid carcinoma.","volume":"96","author":"Pacini","year":"2012","journal-title":"Med Clin North Am"},{"issue":"9871","key":"ooi260045r7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","article-title":"Progress in molecular-based management of differentiated thyroid cancer.","volume":"381","author":"Xing","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"ooi260045r8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1590\/2359-3997000000245","article-title":"Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation.","volume":"61","author":"Schmidt","year":"2017","journal-title":"Arch Endocrinol Metab"},{"issue":"19","key":"ooi260045r9","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma.","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"ooi260045r10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"ooi260045r11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3322\/caac.21389","article-title":"Head and Neck cancers\u2014major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.","volume":"67","author":"Lydiatt","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"ooi260045r12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer.","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"ooi260045r13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41379-019-0327-4","article-title":"\u201cInterchangeability\u201d of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.","volume":"33","author":"Torlakovic","year":"2020","journal-title":"Mod Pathol"},{"issue":"8","key":"ooi260045r14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/PAI.0000000000000256","article-title":"Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.","volume":"23","author":"Phillips","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"11","key":"ooi260045r15","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.5858\/arpa.2015-0544-OA","article-title":"Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue.","volume":"140","author":"Dolled-Filhart","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"ooi260045r16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2050-7771-1-3","article-title":"Sensitive detection of BRAF V600E mutation by amplification refractory mutation system (ARMS)-PCR.","volume":"1","author":"Huang","year":"2013","journal-title":"Biomark Res"},{"issue":"4","key":"ooi260045r17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/thy.2016.0228","article-title":"Programmed death-ligand 1 expression in papillary thyroid cancer and its correlation with clinicopathologic factors and recurrence.","volume":"27","author":"Shi","year":"2017","journal-title":"Thyroid"},{"issue":"38","key":"ooi260045r18","doi-asserted-by":"publisher","first-page":"41228","DOI":"10.18632\/oncotarget.5682","article-title":"Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"ooi260045r19","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"issue":"22","key":"ooi260045r20","doi-asserted-by":"publisher","first-page":"32318","DOI":"10.18632\/oncotarget.8698","article-title":"Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.","volume":"7","author":"Chowdhury","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"ooi260045r21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.radonc.2017.11.027","article-title":"Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy.","volume":"129","author":"Kim","year":"2018","journal-title":"Radiother Oncol"},{"issue":"7","key":"ooi260045r22","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1530\/EC-19-0210","article-title":"Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer.","volume":"8","author":"Aghajani","year":"2019","journal-title":"Endocr Connect"},{"issue":"10","key":"ooi260045r23","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/PAS.0000000000002284","article-title":"PD-L1 expression and its modulating factors in anaplastic thyroid carcinoma: a multi-institutional study.","volume":"48","author":"Agarwal","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"ooi260045r24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12022-020-09630-5","article-title":"Programmed death-ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papillary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma.","volume":"31","author":"Girolami","year":"2020","journal-title":"Endocr Pathol"},{"issue":"1","key":"ooi260045r25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13000-017-0662-z","article-title":"PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.","volume":"12","author":"Bai","year":"2017","journal-title":"Diagn Pathol"},{"issue":"12","key":"ooi260045r26","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.21037\/gs-22-701","article-title":"Combined expression of the BRAFV600E mutation and PD-L1 in early papillary thyroid carcinoma and its relationship with clinicopathological features and recurrence-a retrospective cohort study.","volume":"11","author":"Zhang","year":"2022","journal-title":"Gland Surg"}],"container-title":["JAMA Otolaryngology\u2013Head & Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2852911\/jamaotolaryngology_vasudevan_2026_oi_260045_1791389934.01519.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:00:35Z","timestamp":1791471635000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2852911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2026.2200","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}